{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:08:53Z","timestamp":1789592933753,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002568","name":"University of Ulsan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.aohep.2026.102441","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:20:14Z","timestamp":1789453214000},"page":"102441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of liver function on clinical outcomes in patients with unresectable hepatocellular carcinoma treated with first-line atezolizumab\u2013bevacizumab: an Asia-Pacific multicenter retrospective analysis"],"prefix":"10.1016","author":[{"given":"Yeokyeong","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Wai Meng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-5850","authenticated-orcid":false,"given":"Jonggi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Mook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon L","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-4426","authenticated-orcid":false,"given":"Tsung-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilwhan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-6125","authenticated-orcid":false,"given":"Joycelyn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102441_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102441_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040","volume":"7","author":"Qiu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.aohep.2026.102441_bib0003","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4251\/wjgo.v16.i3.761","article-title":"Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy","volume":"16","author":"Bracco","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.aohep.2026.102441_bib0004","doi-asserted-by":"crossref","first-page":"212","DOI":"10.15403\/jgld-5414","article-title":"The Staging of Newly Diagnosed Hepatocellular Carcinoma in Romania. A National Multicentric Study","volume":"33","author":"Craciun","year":"2024","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.aohep.2026.102441_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102124","article-title":"Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis","volume":"47","author":"Mathurin","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102441_bib0006","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/00365521.2023.2209686","article-title":"Real world for management of hepatocellular carcinoma: a large population-based study","volume":"58","author":"Sethasine","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102441_bib0007","article-title":"Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers","year":"2025","journal-title":"Version 2"},{"key":"10.1016\/j.aohep.2026.102441_bib0008","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2026.102441_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2026.102441_bib0010","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2026.102441_bib0011","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 2022;1:EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"10.1016\/j.aohep.2026.102441_bib0012","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2026.102441_bib0013","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000533859","article-title":"Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab","volume":"102","author":"Kikugawa","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.aohep.2026.102441_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf286","article-title":"First-line atezolizumab\/bevacizumab or durvalumab\/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study","volume":"30","author":"Kournoutas","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.aohep.2026.102441_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21873\/cdp.10295","article-title":"Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B","volume":"4","author":"Kuwano","year":"2024","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.aohep.2026.102441_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/CEG.S256691","article-title":"Safety and Ef fi cacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis","volume":"13","author":"Ogushi","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.aohep.2026.102441_bib0017","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/oncolo\/oyae142","article-title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study","volume":"29","author":"Storandt","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.aohep.2026.102441_bib0018","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/liv.15102","article-title":"Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma","volume":"42","author":"Cheon","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102441_bib0019","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cncr.34559","article-title":"Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice","volume":"129","author":"Nakagawa","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.aohep.2026.102441_bib0020","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/liv.15464","article-title":"Treatment patterns for hepatocellular carcinoma in patients with Child-Pugh class B and their impact on survival: A Korean nationwide registry study","volume":"42","author":"Jeon","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102441_bib0021","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102441_bib0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/gut.48.1.103","article-title":"Hepatocellular carcinoma in Central Europe: prognostic features and survival","volume":"48","author":"Schoniger-Hekele","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2026.102441_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.aohep.2026.102441_bib0024","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/JHC.S492881","article-title":"Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network","volume":"12","author":"Cosgrove","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.aohep.2026.102441_bib0025","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102441_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221080298","article-title":"Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience","volume":"14","author":"de Castro","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.aohep.2026.102441_bib0027","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hepr.13797","article-title":"Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice","volume":"52","author":"Tanaka","year":"2022","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2026.102441_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12072-020-10120-3","article-title":"Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis","volume":"15","author":"Blanc","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.aohep.2026.102441_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.aohep.2026.102441_bib0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/liv.15502","article-title":"Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study","volume":"43","author":"Talbot","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2026.102441_bib0031","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jceh.2023.02.003","article-title":"Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience","volume":"13","author":"Kulkarni","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.aohep.2026.102441_bib0032","doi-asserted-by":"crossref","DOI":"10.1159\/000549955","article-title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","author":"Chan","year":"2025","journal-title":"Liver Cancer"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:25:37Z","timestamp":1789590337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126002619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S1665268126002619"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102441","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of liver function on clinical outcomes in patients with unresectable hepatocellular carcinoma treated with first-line atezolizumab\u2013bevacizumab: an Asia-Pacific multicenter retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102441"}}